RxDoctor Payments Data

Brian Wolfe, MD

Family Medicine · Iola, KSNPI 1396749172

Payments from drug & device makers

$346in general payments, 2019–2025

Across 14 payments — averaging $24.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$113
  • AbbVie$77
  • Acadia Pharmaceuticals Inc$47
  • Medtronic$18
  • Dexcom, Inc.$17
  • Boehringer Ingelheim$16
  • plus $58 from 4 others

What the payments were for

  • Food & beverage$346100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$346 in reported general payments places this provider in the 40th percentile of 1,469 family medicine providers in Kansas.

See all family medicine providers in Kansas

Medicare billing

Part B allowed, 2024
$3,768
Medicare patients
142
Services billed
386

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide148$210,004
XareltoRivaroxaban67$64,401
FarxigaDapagliflozin Propanediol62$63,330
Tresiba Flextouch U-200Insulin Degludec44$59,196
TrulicityDulaglutide42$59,125
EliquisApixaban51$45,179
MyrbetriqMirabegron39$31,941
JardianceEmpagliflozin18$25,030
SymbicortBudesonide/Formoterol Fumarate70$21,919
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$21,863
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr29$17,895
VraylarCariprazine Hcl12$17,075
Breo ElliptaFluticasone/Vilanterol29$16,672
Xigduo XrDapaglifloz Propaned/Metformin11$16,094
MounjaroTirzepatide12$12,459

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$16$210,004148 claims
AstraZenecaFarxiga, Symbicort$15$85,249132 claims
AbbVieVraylar, Linzess$77$27,91230 claims
Boehringer IngelheimJardiance$16$25,03018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,469 family medicine providers in Kansas.

Other family medicine in Iola

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →